First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clini ...

The synthesis of RP-1664, a highly potent, selective and bioavailable PLK4 inhibitor for the potential treatment of cancer, was recently reported by Repare Therapeutics Inc.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

“We continue to advance our selective ITK inhibitor, soquelitinib ... in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The efficacy endpoint for the trial is deep response rate, ...

Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced the appointment of two distinguished oncologists and ...

“Regulatory T cells, a primary mechanism of resistance, can be overcome through higher and more frequent dosing of a conditionally active anti-CTLA-4 antibody. We continue to believe that anti-CTLA-4 ...

We will begin the MacroGenics fourth quarter and full year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only mode, and we will ...